Firebrick Pharma targets US pharmacy launch
- Firebrick Pharma approved a retail launch plan to sell its Nasodine products in US pharmacies following positive feedback at a major trade expo.
- The decision follows an over 200% increase in US online sales for Nasodine during FY26.
- The expansion strategy aims to make US operations self-funded through sales revenues.
Firebrick Pharma (ASX:FRE) has approved a comprehensive strategic plan to enter the US retail pharmacy market with its Nasodine product range.
The board approved the expansion following strong interest from over 20 retail pharmacy groups at a trade expo in Boston, which came after US online sales surged by more than 200% in FY26.
"Phase 1 will be distribution and sales through the independent pharmacy groups that we met at the NACDS," added Dr Peter Molloy, Executive Chairman of Firebrick Pharma Ltd.
The company appointed Al Moghaddam as US Commercial Director to lead retail marketing, leveraging up to six independent regional pharmacy groups representing roughly 700 stores for initial orders.
Firebrick stated that subsequent distribution phases through wholesale banner groups and major retail chains could expand reaching up to 32,000 stores during 2027.
Following the announcement, the Firebrick Pharma share price was unchanged at $0.03.
The pharmaceutical firm recently reported FY26 annual sales of $227,000, representing a 43% year-on-year growth driven by international direct-to-consumer demand.
Firebrick continues to secure intellectual property rights globally while exploring licensing opportunities across international markets to minimise regulatory burdens.
